EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elucidating the Mechanisms of SA–4–1BBL-Mediated Cancer Immunoprevention Through Advanced Informatics Approaches

Mohit Verma iD, Feyza Nur Arguc iD, Mohammad T Malik iD, Pallav Singh iD, Sameep Dhakal iD, Yen On Chan iD, Manish Sridhar Immadi iD, Sabin Dahal, Vahap Ulker iD, Mohammad Tarique iD, Lalit Batra iD, Esma S Yolcu iD und 2 weitere

Biomolecules · 2026

DOI: 10.3390/biom16020252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2026. Verfasst von Mohit Verma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25755, USA. Hauptthemen laut MEDLINE: Neoplasms, Tumor Necrosis Factor Receptor Superfamily, Member 9. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, Missouri Department of Health and Senior Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunoprevention leverages the immune system’s surveillance mechanisms to mitigate tumor development. Vaccines that constitute a tumor antigen and an immune adjuvant are perceived as immunoprevention modalities. However, relevant tumor antigens are unknown for non-viral cancers, which constitute most human cancers. Our group has recently shown that SA–4–1BBL, a novel agonist of CD137 receptor, but not antibodies, shows immunoprevention efficacy against various tumors. Advanced bioinformatics analyses of bulk RNA-seq data were conducted to elucidate mechanisms underlying cancer immunoprevention. Mice received subcutaneous injections of SA–4–1BBL or agonistic 3H3 antibody, and the injection-site tissue (IS) and draining lymph nodes (LN) were analyzed for differential gene expression. SA–4–1BBL induced a compartmentalized and temporally dynamic immune program characterized by early effector activation at IS and sustained immune regulation in draining LN. K-means clustering of 4564 DEGs identified eight functionally distinct clusters. IS-enriched clusters contained activation genes for CD4+ T and NK cells, including Cd28, Klra1, Cd4, Cd40, and Cd40l, while LN clusters were enriched for regulatory genes (Tnfaip3, Irf5, Col1a2) that ensure immune priming and homeostatic restraint for a balanced response. SA–4–1BBL generated a more selective and durable activation of adaptive immunity, TCR signaling, Th1/Th2 differentiation, and NK cytotoxicity. 3H3 activated broader innate inflammatory programs, including Toll-like receptor and neurodegeneration-linked pathways. IMPRes analysis showed that SA–4–1BBL activates sequential immune-regulatory circuits centered on Stat1, Cd247, and Ifng and modulates the CD151–TGF-β axis. These findings demonstrate that SA–4–1BBL elicits a balanced immune response, ensuring both safety and efficacy in preventing cancer development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsTumor Necrosis Factor Receptor Superfamily, Member 9AnimalsMiceImmunoinformaticsHumansGene Expression Regulation, NeoplasticComputational Biology

Stichwörter der Autor:innen

CD137 ligandCD137 pathwaySA–4–1BBLbioinformaticsbulk RNA-seqcancer immunopreventionimmune modulationtranscriptomics

Substanzen

Tumor Necrosis Factor Receptor Superfamily, Member 9

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25755, USA.
  • Christopher S. Bond Life Science Center, University of Missouri, Columbia, MO 65201, USA.
  • Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO 65201, USA.
  • Department of Pediatrics, NextGen Precision Health Institute, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO 65201, USA.
  • Department of Medicine, Envirome Institute, University of Louisville, Louisville, KY 40202, USA.
  • MU Institute for Data Science and Informatics, University of Missouri, Columbia, MO 65201, USA.

ORCID-Profile: Mohit Verma, Feyza Nur Arguc, Mohammad T Malik, Pallav Singh, Sameep Dhakal, Yen On Chan, Manish Sridhar Immadi, Vahap Ulker, Mohammad Tarique, Lalit Batra, Esma S Yolcu, Haval Shirwan, Trupti Joshi

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • Missouri Department of Health and Senior Services
  • National Science Foundation (NSF) Cybersecurity Innovation
  • National Cancer Institute
  • Joan C. Edwards School of Medicine at Marshall University (MURC), Huntington, West Virginia, US
  • National Institute of General Medical Sciences of the National Institutes of Health

Zitieren

APA

Verma, M., Arguc, F. N., Malik, M. T., Singh, P., Dhakal, S., Chan, Y. O., Immadi, M. S., Dahal, S., Ulker, V., Tarique, M., Batra, L., Yolcu, E. S., Shirwan, H., & Joshi, T. (2026). Elucidating the Mechanisms of SA–4–1BBL-Mediated Cancer Immunoprevention Through Advanced Informatics Approaches. Biomolecules. https://doi.org/10.3390/biom16020252

Vancouver

Verma M, Arguc FN, Malik MT, Singh P, Dhakal S, Chan YO, et al. Elucidating the Mechanisms of SA–4–1BBL-Mediated Cancer Immunoprevention Through Advanced Informatics Approaches. Biomolecules. 2026. doi:10.3390/biom16020252

BibTeX
@article{Verma2026,
  author = {Verma, Mohit and Arguc, Feyza Nur and Malik, Mohammad T and Singh, Pallav and Dhakal, Sameep and Chan, Yen On and Immadi, Manish Sridhar and Dahal, Sabin and Ulker, Vahap and Tarique, Mohammad and Batra, Lalit and Yolcu, Esma S and Shirwan, Haval and Joshi, Trupti},
  title = {Elucidating the Mechanisms of SA–4–1BBL-Mediated Cancer Immunoprevention Through Advanced Informatics Approaches},
  journal = {Biomolecules},
  year = {2026},
  doi = {10.3390/biom16020252}
}
Kostenlos starten →